Eventide Asset Management LLC Takes Position in Maze Therapeutics, Inc. $MAZE

Eventide Asset Management LLC purchased a new stake in Maze Therapeutics, Inc. (NASDAQ:MAZE) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 324,041 shares of the company’s stock, valued at approximately $13,425,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in shares of Maze Therapeutics by 27.1% in the 4th quarter. Vanguard Group Inc. now owns 1,697,015 shares of the company’s stock valued at $70,307,000 after acquiring an additional 362,060 shares during the period. Woodline Partners LP increased its holdings in shares of Maze Therapeutics by 10.0% in the 3rd quarter. Woodline Partners LP now owns 1,035,229 shares of the company’s stock valued at $26,843,000 after acquiring an additional 94,529 shares during the period. Marshall Wace LLP increased its holdings in shares of Maze Therapeutics by 9.0% in the 4th quarter. Marshall Wace LLP now owns 847,472 shares of the company’s stock valued at $35,111,000 after acquiring an additional 69,771 shares during the period. ArrowMark Colorado Holdings LLC purchased a new position in shares of Maze Therapeutics in the 3rd quarter valued at $14,135,000. Finally, State Street Corp increased its holdings in shares of Maze Therapeutics by 38.6% in the 4th quarter. State Street Corp now owns 533,005 shares of the company’s stock valued at $22,082,000 after acquiring an additional 148,303 shares during the period.

Maze Therapeutics Price Performance

Shares of MAZE stock opened at $24.05 on Monday. Maze Therapeutics, Inc. has a 1-year low of $9.83 and a 1-year high of $53.65. The stock’s fifty day moving average price is $26.10 and its 200 day moving average price is $36.89. The company has a debt-to-equity ratio of 0.11, a current ratio of 17.88 and a quick ratio of 17.88. The company has a market cap of $1.33 billion, a price-to-earnings ratio of -9.51 and a beta of 2.27.

Maze Therapeutics (NASDAQ:MAZE) last announced its earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The company had revenue of $20.00 million during the quarter. On average, research analysts expect that Maze Therapeutics, Inc. will post -2.76 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on MAZE. Truist Financial cut their price target on Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating on the stock in a report on Tuesday, April 14th. JPMorgan Chase & Co. lifted their price target on Maze Therapeutics from $52.00 to $58.00 and gave the company an “overweight” rating in a report on Tuesday, March 31st. Guggenheim lifted their price target on Maze Therapeutics from $46.00 to $58.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Wall Street Zen upgraded Maze Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Finally, Mizuho upgraded Maze Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 11th. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Maze Therapeutics has an average rating of “Buy” and an average target price of $66.00.

Insiders Place Their Bets

In related news, CEO Jason V. Coloma sold 25,582 shares of the business’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $26.02, for a total transaction of $665,643.64. Following the transaction, the chief executive officer directly owned 350,987 shares in the company, valued at $9,132,681.74. The trade was a 6.79% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Amy Bachrodt sold 2,500 shares of the business’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $29.44, for a total value of $73,600.00. Following the transaction, the senior vice president owned 12,965 shares in the company, valued at approximately $381,689.60. This trade represents a 16.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 89,502 shares of company stock valued at $2,733,139 in the last 90 days. Corporate insiders own 5.30% of the company’s stock.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.